GRAIL Completes $110 Million Equity Financing With Samsung Entities
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) closed a $110 million equity financing with Samsung entities, which purchased common stock at $70.05 per share. The funds are intended to support growth, extend cash runway, and back regulatory and reimbursement efforts for the Galleri multi-cancer early detection test.
GRAIL and Samsung C&T plan to commercialize Galleri in South Korea and may expand to Japan and Singapore, subject to regulatory approvals and other conditions. Initial testing will continue at GRAIL's North Carolina clinical laboratory.
AI-generated analysis. Not financial advice.
Positive
- $110 million equity investment from Samsung entities at $70.05 per GRAL share
- Financing extends cash runway to support regulatory and reimbursement efforts for Galleri
- Strategic collaboration to commercialize Galleri in South Korea with Samsung C&T
- Potential Galleri expansion into additional Asian markets including Japan and Singapore
- Initial Asian testing supported by existing clinical laboratory in North Carolina
Negative
- New equity financing implies share issuance that may dilute existing GRAL shareholders
- Asian Galleri commercialization and expansion remain subject to regulatory approvals and other conditions
News Market Reaction – GRAL
On the day this news was published, GRAL gained 3.08%, reflecting a moderate positive market reaction. This price movement added approximately $83M to the company's valuation, bringing the market cap to $2.77B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
GRAL was up about 5–6% pre‑news while key diagnostics peers like NEO, TWST and CDNA also traded higher, but no peers appeared in the momentum scanner, pointing to a stock‑specific move rather than a clear sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 31 | Clinical trial data | Positive | -10.2% | Full PATHFINDER 2 results showing Galleri substantially increased cancer detection. |
| May 27 | Equity grants | Neutral | +3.5% | Inducement RSU awards to new employees under Nasdaq Listing Rule 5635(c)(4). |
| May 26 | Conference presentation | Neutral | +3.6% | Announcement of presentation at Goldman Sachs Global Healthcare Conference. |
| May 21 | Conference presentation | Neutral | -1.0% | Announcement of presentation at the 2026 Jefferies Global Healthcare Conference. |
| May 05 | Earnings update | Positive | +15.3% | Q1 2026 results with strong Galleri growth and FDA PMA review acceptance. |
GRAL has reacted positively to earnings but showed a sharp selloff on strong clinical data, indicating inconsistent responses to ostensibly positive catalysts.
Regulatory & Risk Context
Short interest is moderately elevated, suggesting room for pronounced upside or downside swings if sentiment shifts or liquidity tightens.
Market Pulse Summary
This announcement brings a $110 million strategic equity investment from Samsung at $70.05 per share, reinforcing GRAIL’s cash position and Asian expansion plans. Investors may weigh this against recent insider net selling and elevated short positioning going forward.
Key Terms
equity financing financial
regulatory approval regulatory
multi-cancer early detection test medical
AI-generated analysis. Not financial advice.
Pursuant to the definitive agreement, the Samsung entities invested
"This investment from the Samsung entities further strengthens our balance sheet and extends our cash runway as we advance key priorities, including securing regulatory approval and reimbursement for Galleri® in
As previously announced, GRAIL and Samsung C&T Corporation intend to collaborate to commercialize the Galleri multi-cancer early detection test in
"GRAIL is at a pivotal moment in its mission to transform early cancer detection. This investment in GRAIL, together with the strategic business collaboration, represents a significant milestone in advancing Samsung C&T's vision expanding access to cancer early detection. We are excited to bring the benefits of innovative screening technologies to more people in
Latham & Watkins LLP served as legal advisor and Morgan Stanley & Co. LLC served as financial advisor to GRAIL. Samsung was advised by Covington & Burling, BKL, and E&Y Han Young (
About Samsung C&T Corporation
Samsung C&T Corporation, a dynamic player in industries ranging from construction, trading, fashion and resorts, is actively expanding its portfolio with strategic investments in the fields of biopharmaceutical and life sciences. Since its investment in Samsung Biologics and Samsung Epis Holdings, Samsung C&T continues to invest in innovative technologies and businesses within the bio and healthcare sectors, with the goal of contributing to improving the quality of human life.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
About Galleri®
The Galleri® multi-cancer early detection (MCED) test screens for more than 50 cancer types, including many deadly cancers that currently lack screening options, such as pancreatic, ovarian and liver/bile duct cancers1. The Galleri test is the only MCED test clinically proven through a randomized controlled trial to increase earlier cancer detection (Stage I-III) and reduce Stage IV diagnoses - enabling more patients to have access to potentially curative treatment options2. When added to standard-of-care screening, the Galleri test reduced Stage IV diagnosis by more than
For more information, visit galleri.com.
*A statistically significant reduction was not observed in combined stage III–IV diagnoses across three screening rounds for 12 cancer types responsible for around two-thirds of cancer mortality in the US and UK.
**Test performance metrics do not represent results of a head-to-head comparative study. Separate studies have different designs, objectives, and participant populations, which limits the ability to draw conclusions about comparative performance.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
GRAIL Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations about future collaborations among us, Samsung entities or Samsung investors including Samsung C&T Corporation, future initial testing, future reimbursement, future potential additional collaborations, our ability to commercialize Galleri in other geographies, and our cash runway and the sufficiency of cash on hand to finance our business and anticipated trends in our business.
These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the sections entitled "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2024 and in our Quarterly Report on Form 10-Q for the period ended September 30, 2025 (the "Form 10-Q"). Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results, financial condition and success in our business strategies and operations may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.
1 Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
2 Swanton C. NHS-Galleri: Primary Results From a Randomised Controlled Trial to Assess the Clinical Utility of a Multi-Cancer Early Detection (MCED) Test in Population Screening [presentation]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 29-June 2.
3 GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-completes-110-million-equity-financing-with-samsung-entities-302810720.html
SOURCE GRAIL, Inc.